Compare Cassava Sciences Inc (FLNA) vs Fubotv Inc (FUBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Fubotv Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Fubotv Inc trades at $8.84 (market cap $1.02B). The key difference: Fubotv Inc is far larger — about 25.9× Cassava Sciences Inc's market cap, and Fubotv Inc is more actively traded (978,631 versus 759,018). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Fubotv Inc for 35 Days on average.
| FLNA | FUBO | |
|---|---|---|
Market Cap | $39.40M | $1.02B |
Volume | 759,018 | 978,631 |
Sector | Health | Media |
52-Week High | $4.64 | $48.96 |
52-Week Low | $0.68 | $8.09 |
Typical Hold Time | 37 Days | 35 Days |
Enterprise Value | -$43.28M | $1.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.
The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.
FUBO trades at $9.35, up 1.08% with bearish technical signals but attractive valuation metrics including P/E of 2.43 and P/S of 0.19. The company shows improving financials with revenue growth to $1.62B in 2024 and projected profitability in 2025. Recent developments include new sports streaming agreements and Disney partnership integration driving subscriber growth.
FUBO presents a turnaround opportunity with deep valuation discounts and projected EBITDA growth, though execution risks remain high. The stock offers significant upside to analyst consensus target of $63.38 but faces challenges from persistent cash burn and competitive streaming landscape. Investors should weigh the potential for operational improvements against ongoing financial volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →
